Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits
- Magda Luzia Neves1,
- Letícia Yamasaki2,
- Osimar de Carvalho Sanches2,
- Marcelo Sávio Paiva do Amaral3,
- Helaine Stevanin3,
- Rogério Giuffrida4,
- Eudes Ramalho Candido4,
- Jonatas Eduardo Góes4,
- Luís Felipe da Costa Zulim4,
- Augusto Schweigert5,
- Rosimery Missuzu Fukui5,
- Carlos Collares Meirelles5,
- Carolina Akemi Sasaki5 and
- Silvia Franco Andrade6Email author
© Neves et al.; licensee Springer. 2013
Received: 11 September 2012
Accepted: 12 September 2012
Published: 3 January 2013
The objective of this study was to evaluate the effectiveness of various linseed oil (LO) preparations (oral, topical, oral and topical combined) in treating experimentally induced keratoconjunctivitis sicca (KCS) in rabbits. Twenty male New Zealand white rabbits were divided into four groups: group C (control), group OLO (oral LO), group TLO (topical LO), and group OTLO (oral and topical LO). The animals were evaluated weekly using Schirmer's tear test (STT), fluorescein test (FT), and Rose Bengal test (RBT) and were euthanized at the end of the experiment for histopathological analysis.
There were significant improvements in the parameters analyzed (STT, FT, and RBT) and in the histopathological finding in all of the groups using LO.
The analyzed results demonstrate that LO, administered orally or topically, was effective in treating experimentally induced KCS in rabbits, although combined oral and topical LO did not show additional benefits greater than those with a single route of administration.
KeywordsHistopathology Keratoconjunctivitis sicca Linseed oil Omega 3 and 6 Rabbits
Keratoconjunctivitis sicca (KCS), or dry eye syndrome, is characterized by chronic inflammation of the cornea, conjunctiva, and lacrimal glands caused by quantitative and/or qualitative tear changes . Recently, several studies have proven that essential fatty acids (EFAs), omega-3 (ω-3) and omega-6 (ω-6), administered orally are an alternative therapy for patients with various types of tear deficiency, including Sjögren's syndrome and KCS [2–6]. Additionally, the topical use of ω-3 and ω-6 effectively controlled the signs of experimentally induced inflammation in rats with KCS .
Eicosanoids are biologically active substances that regulate physiological processes and are lipid mediators of inflammation. From the ω-6 EFA-derived prostanoids, arachidonic acid, via cyclooxygenase 1 (COX1) pro-inflammatory mediators, is synthesized, including prostaglandin (PGE2), thromboxane (TXA2), prostacyclin (PGI2), and the leukotrienes (LTA4, LTB4, LTC4, and LTD4). However, non-inflammatory mediators (PGE1 and TXA1) are also synthesized from the EFA series of ω-6 by the action of COX1 on dihomo-γ-linoleic acid (DGLA) and from the EFA series of ω-3 by the action of COX1 on eicosapentaenoic acid (PGE3, PGI3, and TXA3) as well as by the actions of lipoxygenase (LTA5, LTB5, LTC5, and LTD5) and of docosahexaenoic acid [2, 4].
The ω-3 and ω-6 EFAs are found in many foods, such as nuts, cold-water fish, soybeans, rapeseed oil, and linseed oil. Linseed, Linum usitatissimum, is composed of 57% ω-3, 16% ω-6, 28% monounsaturated fatty acids, and only 9% unsaturated fatty acids, and the ω-3-to-ω-6 ratio of 1:3 is considered close to ideal. Linseed is considered to be a natural anti-inflammatory agent due its potential in synthesizing non-inflammatory mediators, such as PGE1 and TXA1 [8–10]. The objective of this study was to evaluate the effectiveness of various linseed oil (LO) preparations (oral, topical, oral and topical combined), which are rich in ω-3 and ω-6, in treating experimentally induced KCS in rabbits.
Materials and methods
Twenty male New Zealand white rabbits (Oryctolagus cuniculus) were housed in individual metal cages with water and food ad libitum. All of the procedures were approved by the Ethics Committee on the Use of Animals of UNOESTE under protocol no. 014/09. The induction model of KCS in rabbits was based on a previously published study , which described the removal of the lacrimal glands and nictitating membranes and the administration of atropine sulfate 1% eye drops TID until the confirmation of KCS diagnosis (≤5 mm/min Schirmer's tear test (STT) and/or Rose Bengal test (RBT) positive) and then throughout the treatment period (12 weeks) for KCS maintenance. The rabbits were evaluated at M0 (prior to the KCS induction surgery), M1 (1 week after the induction of KCS and the beginning of treatment), and M2 to M12 (i.e., assessments as weekly intervals beginning 1 week after the initiation of treatment). Of the 20 rabbits, 15 were induced using the KCS protocol described above and 5 were allocated to the control group without KCS induction. A week after the induction of KCS, the groups of animals were treated for 12 weeks as follows: group C (n = 5, control, one drop of placebo, 0.9% NaCl solution, topically twice a day (BID) in both eyes), group OLO (n = 5, 1 g/day of liquid LO made by Laboratory Ophthalmos-SP (São Paulo, Brazil) orally), group TLO (n = 5, one drop of LO eye drops made by Laboratory Ophthalmos-SP BID in both eyes), and group OTLO (n = 5, 1 g/day of liquid LO orally with one drop of LO eye drops BID in both eyes). STT was performed without anesthetic eye drops and was considered positive if the KCS values were ≤5 mm/min. The fluorescein test (FT) was performed to observe ulcers colored with 1% fluorescein strips moistened with a small amount of normal saline; they were scored 1 (negative for a corneal ulcer) or 2 (positive for a corneal ulcer). RBT was performed on stained cells devitalized by KCS; after instilling the anesthetic eye drops, we used one drop of 0.5% Rose Bengal, and they were scored 1 (the absence of stained cells devitalized by KCS) or 2 (the presence of stained cells devitalized by KCS). For the histopathological analysis at the end of the experiment (M12), the rabbits were euthanized using 2.5% IV sodium thiopental (200 mg/kg); after transpalpebral enucleation, the eyeball was placed in a solution of 10% formaldehyde for 24 to 48 h. The eyes were stored in 70% alcohol and were processed according to the technique for inclusion in paraffin; 5-μm-thick cuts of the cornea and conjunctiva were obtained, which were colored with hematoxylin and eosin (HE) as well as periodic acid-Schiff (PAS). For STT variables and the density of caliciform cells, we used the variance analysis test for paired samples in contrast to Tukey's method. For FT, RBT, and histopathology, a non-parametric Friedman test was used to compare the various times, and the Kruskal-Wallis test with Dunn's method was used for between-group comparisons. We adopted a significance level of P < 0.05.
Discussion and Conclusions
The group treated with oral LO (group OLO) had normal tear production in the second week after starting treatment and a significant increase above the control group after 3 weeks. This finding is consistent with several studies, especially in patients with Sjögren's syndrome, in whom oral ω-3 and ω-6 supplementation has been recommended to control KCS symptoms [2–4, 12]. In this study, topical LO was more effective in the early treatment of KCS, increased production of tears, and corneal ulcer resolution. The lipid mediators play an important role in the resolution and repair of corneal injuries [7, 12, 13].
The LO mechanism of action might be anti-inflammatory; the inhibitory response of the arachidonic acid inflammatory cascade has been proven to synthesize the non-inflammatory mediators PGE1 and TXA1 from ω-6 series by the action of COX1 on DGLA, which likely reduces the inflammation on the cornea, conjunctiva, and lacrimal glands; increases the production of tears; and improves the activity of caliciform cells, consequently causing an increase in the production of mucin. This increased mucin provides an improvement in the PTF quality, which leads to reduced tear evaporation in the aqueous portion of the eye [2, 4, 6, 7, 12]. In this study, LO topical instillation did not induce any ocular side effects, such as irritation, hyperemia, or discomfort. In addition, the concomitant use of LO orally and topically did not show benefits beyond a single route of administration. A hypothesis for this result is that an excess of ω-3 and ω-6 results in an improper ratio of these two EFAs. More pharmacokinetic and pharmacodynamic studies of oral LO and of LO in ocular topical formulations should be conducted to clarify these results. Therefore, we conclude that LO, orally and topically, was effective in treating experimentally induced KCS in rabbits, although combined oral and topical LO did not demonstrate additional benefits beyond those from a single route of administration.
We would like to thank the Post-Graduate Program in Animal Science of UNOESTE for the financial support and the Laboratory Ophthalmos-SP for the donation of some of the materials necessary for the execution of the experiment.
- Stevenson W, Chauhan SK, Dana R: Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012, 130: 90–100. 10.1001/archophthalmol.2011.364PubMed CentralPubMedView Article
- Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G: Systemic linoleic and g-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003, 22: 97–101. 10.1097/00003226-200303000-00002PubMedView Article
- Sullivan B, Cermak J, Sullivan R, Papas AS, Evans JE, Dana MR, Sullivan DA: Correlation between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren’s syndrome. Adv Exper Med Biol 2002, 506: 441–447.
- Roncone M, Bartlett H, Eperjesi F: Essential fatty acids for dry eye: a review. Contact Lens & Anterior Eye 2010, 33: 49–54. 10.1016/j.clae.2009.11.002View Article
- Jiucheng H, Bazan HEP: Omega-3 fatty acids in dry eye and corneal nerve regeneration after refractive surgery. Prostaglandins Leukot Essent Fatty Acids 2010, 82: 319–325. 10.1016/j.plefa.2010.02.004View Article
- Wojtowicz JC, Butovich I, Uchiyama E: Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011, 30: 308–314. 10.1097/ICO.0b013e3181f22e03PubMedView Article
- Rashid S, Jin Y, Ecoiffer T, Barabino S, Schaumberg DA, Dana MR: Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008, 126: 210–225.View Article
- Oomah BD: Flaxseed as functional source. J Sci Food Agricult 2001, 81: 889–894. 10.1002/jsfa.898View Article
- Covington MB: Omega-3 fatty acids. Am Fam Physic 2004, 70: 133–140.
- Hassan-Zadeh A, Sahari MA, Barzegar M: Optimization of the omega-3 extraction as a functional food from flaxseed. Int J Food Sci Nut 2008, 59: 526–534. 10.1080/09637480701565935View Article
- Gomes JAP, Cavalho FV, Barros OS, Dantas CM, Dias AKG, Pinheiro RK, Peres MFP: Modelo experimental de olho seco em coelho. Arq Bras Oftalmol 1994, 57: 264–269.
- Aragona P, Bucolo C, Spinella R, Giuffrida S, Ferreri G: Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sjögren’s syndrome patients. Investig Ophthalmol Vis Sci 2005, 46: 4474–4479. 10.1167/iovs.04-1394View Article
- Kenchegowda S, Bazan HEP: Significance of lipid mediators in corneal injury and repair. J Lipidic Res 2010, 51: 879–891. 10.1194/jlr.R001347View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.